Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-11-16
2004-08-31
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S027220
Reexamination Certificate
active
06784165
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the use of particular adenosine A
1
agonists belonging to a class of N
6
-substituted-5′-(N-substituted) carboxamidoadenosines in the treatment of heart rhythm disturbances in mammals, and to novel dosage forms for practicing this new use.
2. Related Art
In the mammalian heart, in order to circulate blood, contraction of the ventricles is initiated by an electrical impulse in the sinoatrial (SA) node that then passes through the atrioventricular (AV) node to the ventricles. Consistent rhythmic impulses produce a regular heart beat when the heart is functioning normally.
Various dysfunctions can occur in the heart to disturb the regular heart beat pattern and produce arrhythmias. For example, a condition of excessively rapid heart beats can occur that is defined as tachycardia. Tachycardia can originate from excessively rapid discharges from a malfunctioning SA node, electrical impulses passing through accessory pathways that prompt beats before they would normally occur, or re-entry of impulses in the AV node. In such cases, the disorder has been referred to as paroxsymal supraventricular tachycardia (PSVT), which in some patients can progress to congestive heart failure. Another heart rhythm disturbance, referred to as atrial fibrillation/flutter (AF), is characterized by a rapid and disordered beating of the atria, and is associated with an increased incidence of stroke. The above described heart rhythm disturbances can be classified as supraventricular tachyarrhythmias. Symptoms of these disorders can include discomfort due to palpitations, fatigue, dyspnea, as well as a sensation of lightheadedness and/or dizziness.
Adenosine is well-known to slow heart rate (negative chronotropic effect) and slow impulse conduction through the AV node (negative dromotropic effect) (Berne et al., U.S. Pat. No. 4,673,563; Belardinelli et al.,
Journal of Pharmacology and Experimental Therapeutics
271: 1371(1994)). Adenosine is currently used in the treatment of PSVT, but it has not proven efficacious in converting AF to normal sinus rhythm.
Adenosine acts through multiple receptor subtypes, termed A
1
, A
2A
, A
2B
, and A
3
. The adenosine A
1
receptor mediates adenosine's negative chronotropic and negative dromotropic effects as well as directly depressing atrial (but not ventricular) contractility. The adenosine A
2A
receptor mediates adenosine's action of dilating coronary arteries. The localization and function of adenosine A
2B
and A
3
receptors in the heart have not been well defined.
Since PSVT can result from abnormally frequent impulses affecting the AV node and since the adenosine A
1
receptor mediates adenosine's negative dromotropic effect, one strategy to terminate PSVT is to use a selective adenosine A
1
receptor agonist to slow impulse conduction through the AV node (Belardinelli et al.,
Journal of Pharmacology and Experimental Therapeutics
271: 1371 (1994); Snowdy et al.,
British Journal of Pharmacology
126: 137 (999)).
However, adenosine A
1
receptor agonists that have been heretofore studied for this purpose lacked the necessary potency, selectivity, oral bioavailability and/or pharmacodynamic activity. In addition, prior art adenosine A
1
agonists have also been shown to be hypotensive, a side effect that would worsen symptoms of patients experiencing heart rhythm disturbances.
A series of N
6
-substituted-5′-(N-substituted)carboxamidoadenosine derivatives have been previously described. These compounds are selective adenosine A
1
receptor agonists (Olsson, R. and Thompson, R., U.S. Pat. No. 5,310,731), having utility as vasodilatory or anti-hypertensive agents.
SUMMARY OF THE INVENTION
The present invention is directed to a method for treatment of heart rhythm disturbances in a mammal that would benefit from the induction of negative dromotropic action, negative chronotropic action, or a combination thereof, comprising:
administering to a mammal in need of such treatment an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt or ester thereof, wherein
R
1
is C
3-7
secondary alkyl, C
3-8
cycloalkyl, or C
7
bicycloalkyl; and
R
2
is C
1-4
alkyl, C
1-4
hydroxyalkyl or C
3-5
cycloalkyl.
Such heart rhythm disturbances include supraventricular tachyarrhythmias, such as paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation/flutter (AF).
The present invention is also directed to novel intravenous and oral dosage forms comprising particular concentrations of one or more compounds of Formula I.
The present invention is also directed to the use of a compound of Formula I in the manufacture of a medicament for treating heart rhythm disturbances in a mammal that would benefit from the induction of negative dromotropic action, negative chronotropic action, or a combination thereof.
REFERENCES:
patent: 3502649 (1970-03-01), Thiel et al.
patent: 3509129 (1970-04-01), Kampe et al.
patent: 3590029 (1971-06-01), Koch et al.
patent: 3781273 (1973-12-01), Kampe et al.
patent: 3851056 (1974-11-01), Stork et al.
patent: 3901876 (1975-08-01), Vorbrüggen et al.
patent: 3931401 (1976-01-01), Prasad et al.
patent: 3966916 (1976-06-01), Kampe et al.
patent: 4029884 (1977-06-01), Stein et al.
patent: 4090021 (1978-05-01), Vorbrüggen
patent: 4167565 (1979-09-01), Stein et al.
patent: 4224438 (1980-09-01), Fauland et al.
patent: 4514405 (1985-04-01), Irmscher et al.
patent: 4673563 (1987-06-01), Berne et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4738954 (1988-04-01), Hamilton et al.
patent: 4764604 (1988-08-01), Müller
patent: 4868160 (1989-09-01), Hamilton et al.
patent: 5024998 (1991-06-01), Bodor
patent: 5032583 (1991-07-01), Evans
patent: 5219839 (1993-06-01), Bru-Magniez et al.
patent: 5219840 (1993-06-01), Gadient et al.
patent: 5310731 (1994-05-01), Olsson et al.
patent: 5364862 (1994-11-01), Spada et al.
patent: 5424297 (1995-06-01), Rubio et al.
patent: 5789416 (1998-08-01), Lum et al.
patent: 6048865 (2000-04-01), Baraldi
patent: RE37045 (2001-02-01), Olsson et al.
patent: 6211165 (2001-04-01), Liang et al.
patent: 6307054 (2001-10-01), Truesdale et al.
patent: 6329349 (2001-12-01), Liang et al.
patent: 2 007 273 (1971-08-01), None
patent: 0 169 009 (1986-01-01), None
patent: 58-167599 (1983-10-01), None
patent: WO 99/24450 (1999-05-01), None
patent: WO 99/24450 (1999-08-01), None
patent: 67/7630 (1968-04-01), None
Belardinelli, L. et al., “The Cardiac Effects of a Novel A1-Adenosine Receptor Agonist in Guinea Pig Isolated Heart,”J. Pharmacol.&Experimental Therapeut. 271:1371-1382, The American Society for Pharmacology and Experimental Therapeutics (1994) (Issue No. 3; Dec., 1994).
Daly, J.W., “Adenosine Receptors: Targets for Future Drugs,”J. Med. Chem. 25:197-207, American Chemical Society (1982) (Issue No. 3; Mar., 1982).
Daly, J.W. et al., “Structure-Activity Relationships for N6-Substituted Adenosines at a Brain A1-Adenosine Receptor with a Comparison to an A2-Adenosine Receptor Regulating Coronary Blood Flow,”Biochem. Pharmacol. 35:2467-2481, Pergamon Journals Ltd. (1986) (Issue No. 15; Aug. 1, 1986).
Fleysher, M.H. et al., “Synthesis and biological activity of some new N6-substituted purine nucleosides,”Chem. Abstracts 72:349, Abstract No. 3706g, American Chemical Society (1970) (Jan. 5, 1970).
Fox, I.H. and L. Kurpis, “Binding Characteristics of an Adenosine Receptor in Human Placenta,”J. Biol. Chem. 258:6952-6955, American Society of Biological Chemists, Inc. (1983) (Issue No. 11; Jun. 10, 1983).
Goodman, L., “Chemical Syntheses and Transformations of Nucleosides,” in:Basic Principles in Nucleic Acid Chemistry, Ts'o, P.O.P., ed., Academic Press, New York, publ., pp. 150-151 (1974).
Kenakin, T.P. and N.B. Pike, “An in vitro analysis of purine-mediated renal vasoconstriction in rat isolated kidney,”Br. J. Pharmac. 90:373-381, The Macmillan Press Ltd. (1987) (Issue No. 2; Feb., 1987).
Olsson, R.A. et al., “Use of Structure-Activity Relationships in the Study of Adenosin
Aderis Pharmaceuticals, Inc.
Crane L E
Sterne Kessler Goldstein & Fox P.L.L.C.
Wilson James O.
LandOfFree
Treatment of heart rhythm disturbances with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of heart rhythm disturbances with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of heart rhythm disturbances with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3357637